IP Library › Granted Patent US 12,576,157
Granted Patent B2
US 12,576,157 · App. 18/352,791 · Granted Mar 17, 2026

Peptide saporin conjugate for the treatment of cancer

Inventors: Kathlynn C. Brown (Staunton, VA); Curtis Allred (Menlo Park, CA); Michael McGuire (Harrisonburg, VA)
Assignee: SRI International
A61K47/6415A61K38/168A61K45/06A61K47/60A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,157
App. No.
18/352,791
Granted
Mar 17, 2026
Kind
B2
Abstract

Disclosed herein, are compositions comprising one or more a molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer.

Claims (9)

1 . A molecular guidance system (MGS) peptide of amino acid sequence selected from CH 3 CO-FHAVPQSFYT-PEG 11 -C-NH 2 (SEQ ID No: 76), and FHAVPQSFY (SEQ ID NO: 78).

2 . The MGS peptide of claim 1 , wherein the MGS peptide is covalently attached to a cytotoxic agent, directly or through a linker.

3 . The MGS peptide of claim 2 , wherein the linker comprises polyethylene glycol (PEG).

4 . The MGS peptide of claim 3 , wherein the cytotoxic agent comprises saporin and is covalently attached to PEG, directly or through a linker.

5 . A composition comprising one or more cytotoxic agents conjugated to one or more molecular guidance system (MGS) peptides selected from:

LQWRRNFGVWARYRL (SEQ ID NO: 31), CH 3 CO-LQWRRNFGVWARYRL, CH 3 CO-LQWRRNFGVWARYRL-PEG 11 -C-NH 2 (SEQ ID NO: 72), CH 3 CO-FHAVPQSFYT-PEG 11 -C-NH 2 (SEQ ID NO: 76), FHAVPQSFY (SEQ ID NO: 78), and CH 3 CO-YAAWPASGAWT-PEG 11 -C-NH 2 (SEQ ID NO: 71).

6 . The composition of claim 5 , wherein the composition comprises two MGS peptides conjugated to the one or more cytotoxic agents via one or more chemical linkers, wherein the one or more chemical linkers are covalently linked to one another to form a dimeric structure, and wherein the MGS peptides are not directly linked to each other.

7 . The composition of claim 5 , wherein the composition comprises four MGS peptides conjugated to the one or more cytotoxic agents via one or more chemical linkers, wherein the one or more chemical linkers are covalently linked to one another and form a tetrameric structure, and wherein the MGS peptides are not directly linked to each other.

8 . The composition of claim 5 , wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2023
From: BROWN, KATHLYNN C.; ALLRED, CURTIS; MCGUIRE, MICHAEL
To: SRI INTERNATIONAL
Reel/Frame 064843/0446 →
Continuity (3)
Continuation 16629803
Provisional Application 62530674 · Jul 10, 2017
Related Publication 20240024495A1 · Jan 25, 2024
References Cited (75)
US 8241623B1 · Bermudes · 2012 [cited by applicant]
US 8524220B1 · Bermudes · 2013 [cited by applicant]
US 8623350B1 · Bermudes · 2014 [cited by applicant]
US 9068187B1 · Bermudes · 2015 [cited by applicant]
US 10925960B2 · Brown · 2021 [cited by examiner]
US 11738089B2 · Brown · 2023 [cited by examiner]
US 11965004B2 · Brown · 2024 [cited by examiner]
US 20050288492A1 · Rabbitts et al. · 2005 [cited by applicant]
US 20060239968A1 · Arap et al. · 2006 [cited by applicant]
US 20080206136A1 · Greene et al. · 2008 [cited by applicant]
US 20090110662A1 · Breitenkamp et al. · 2009 [cited by applicant]
US 20100247589A1 · Fahnestock et al. · 2010 [cited by applicant]
US 20110281354A1 · Stayton et al. · 2011 [cited by applicant]
US 20120141478A1 · Coupade · 2012 [cited by applicant]
US 20120208742A1 · Primiano et al. · 2012 [cited by applicant]
US 20120283410A1 · Mirosevich et al. · 2012 [cited by applicant]
US 20140022045A1 · Jang et al. · 2014 [cited by applicant]
US 20140094404A1 · Villaverde Corrales · 2014 [cited by examiner]
US 20150071862A1 · Sabatino et al. · 2015 [cited by applicant]
US 20150203557A1 · Debinski et al. · 2015 [cited by applicant]
US 20150315594A1 · Prakash et al. · 2015 [cited by applicant]
US 20160310607A1 · Ryves · 2016 [cited by applicant]
US 20170281752A1 · Brown et al. · 2017 [cited by applicant]
US 20190077752A1 · Lerchen · 2019 [cited by examiner]
US 20220227823A1 · Brown et al. · 2022 [cited by applicant]
AU 2018301651 · 2019 [cited by applicant]
AU 2018301804 · 2019 [cited by applicant]
CN 1816352A · 2006 [cited by applicant]
CN 101724073A · 2010 [cited by applicant]
CN 111278847 · 2020 [cited by applicant]
CN 111417646 · 2020 [cited by applicant]
EP 2018831080 · 2020 [cited by applicant]
EP 2018831318 · 2020 [cited by applicant]
JP 2014508515A · 2014 [cited by applicant]
JP 2020501231 · 2020 [cited by applicant]
JP 2020501210 · 2020 [cited by applicant]
WO 2009089186A2 · 2009 [cited by applicant]
WO WO2012040513 · 2012 [cited by examiner]
WO WO2012040513A1 · 2012 [cited by examiner]
WO 2012095527A1 · 2012 [cited by applicant]
WO 2012177868A1 · 2012 [cited by applicant]
WO 2016022597A1 · 2016 [cited by applicant]
WO 2016100748A1 · 2016 [cited by applicant]
WO 2018114798A1 · 2018 [cited by applicant]
WO 2019014190A1 · 2019 [cited by applicant]
WO 2019014199A1 · 2019 [cited by applicant]
WO 2004003170A2 · 2024 [cited by applicant]
Bartlett “Exploiting Chemical Diversity for Drug Discovery” Edited by Paul A Bartlett and Michael Entzeroth, The Royal Society of Chemistry, 2006, pp. 113-118. [cited by examiner]
“Find ETDs Home » Thesis Resources » Find ETDs” Online: “https://ndltd.org/thesis-resources/find-etds/” Accessed Jan. 31, 2023. [cited by examiner]
Irwin “ZINC—A Free Database of Commercially Available Compounds for Virtual Screening” J. Chem. Inf. Model. 2005, 45, 177-182. [cited by examiner]
Kim “PubChem in 2021: new data content and improved web interfaces” Nucleic Acids Research, 2021, vol. 49, Database issue Published online Nov. 5, 2020. [cited by examiner]
STN Registry/Zregistry (CAS Registrysm) Sep. 2016 2 pages. [cited by examiner]
Umlauf, Bioconjugate Chemistry (2014), 25(10), 1829-1837. [cited by examiner]
Bruno , Ther Deliv. Nov. 2013 ; 4(11): 1443-1467. [cited by examiner]
Drazic, Biochimica et Biophysica Acta (BBA)—Proteins and Proteomics, vol. 1864, Issue 10, Oct. 2016, pp. 1372-1401. [cited by examiner]
Feldman, Understanding ‘Evergreening’ : Making Minor Modifications Of Existing Medications To Extend Protections, Health Affairs Jun. 2022 41:6, 801-804. [cited by examiner]
Dwivedi, Evergreening: A deceptive device in patent rights, Technology in Society 32 (2010) 324-330. [cited by examiner]
McGuire, Scientific Reports 4 : 4480, 1-11, 2014. [cited by examiner]
Rabideau, ACS Cent. Sci. 2015, 1, 423-430. [cited by examiner]
Venkatesh et al., “Role of the Development Scientist in Compound Lead Selection and Optimization”, J. Pharm. Sci. 89, 145-154 (2000) pp. 145-154. [cited by applicant]
J. G. Cannon, “Analog Design” Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice, Wiley Interscience 1995, pp. 783-802. [cited by applicant]
Giansanti, F. et al. “PDZ domain in the engineering and production of a saporin chimeric toxin as a tool for targeting cancer cells: PDZ-mediated targeting of saporin toxin”, Journal of Cellular Biochemistry, vol. 116, … [cited by applicant]
Kuang, H. et al. “The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery”, Advanced drug delivery reviews, vol. 110, Aug. 2016, p. 80-101. [cited by applicant]
Lim, K.J. et al. “A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells”, Jun. 1, 2013, PLOS One, vol. 8, No. 6, p. e66084. [cited by applicant]
Mcguire, et al. Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer. Scientific Reports, Mar. 27, 2014, vol. 4, Article 4480, pp. 1-11. [cited by applicant]
Umlauf, BJ. et al. “Modular three-component delivery system facilitates HLA class I antigen presentation and CD8+ T-cell activation against tumors”, Molecular Therapy, vol. 23, No. 6, Jun. 2015, pp. 1092-1102. [cited by applicant]
Umlauf, BJ. et al. “Identification of a novel lysosomal trafficking peptide using phage display biopanning coupled with endocytic selection pressure”, Bioconjugate Chemistry, vol. 25, No. 10, Oct. 2014, pp. 1829-1837. [cited by applicant]
Zhou, et al., “Cell-specific delivery of a chemotherapeutic to lung cancer cells”, Journal of the American Chemical Society, vol. 126, No. 48, Dec. 8, 2004, pp. 15656-15657. [cited by applicant]
International Search Report and Written Opinion were mailed on Dec. 4, 2018 by the International Searching Authority for International Application No. PCT/US2018/041412, filed on Jul. 10, 2018 and published as WO/2019/0… [cited by applicant]
International Preliminary Report on Patentability was mailed on Jan. 14, 2020 by the International Searching Authority for International Application No. PCT/US2018/041412, filed on Jul. 10, 2018 and published as WO/2019… [cited by applicant]
Brown, “Pettidic Tumor Targeting Agents the Road from Phage Display Peptide Selections to Clinical Applications”, Currnet Pharmaceutical Design, 16(9):1040-1054 (Mar. 1, 2010). [cited by applicant]
Guthi et al., “MRI-Visible Micellar Nanomedicine for Targeted Drug Delivery to Lung Cancer Cells”, Mol Pharm, 7(1):32-40 (Feb. 1, 2010). [cited by applicant]
Kuzmin et al., “Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I”, Bulletin of Experimental Biology and Medicine, 162(6):754-757—(Apr. 20, 2017). [cited by applicant]
Singh et al., “Dimerization of a Phage-Display Selected Peptide for Imaging of αvβ—Integrin: Two Approaches to the Multivalent Effect”, Theranostics, 4(7): 745-760 (May 15, 2014). [cited by applicant]
Tai et al., “Functional peptides for 1-14 siRNA delivery”, Advanced Drug Delivery Reviews, 110-111:157-168 (Aug. 13, 2016). [cited by applicant]